Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Subscribe To Our Newsletter & Stay Updated